Ambrose CS, Israel E, Bowen K, Llanos JP, et al. Ambrose, et al. Reply to: Disconnect for Tezepelumab on Exacerbations, Symptoms and Quality of Life in Type 2 Low Asthma. Am J Respir Crit Care Med 2023 Jun 6. doi: 10.1164/rccm.202305-0843.
PMID: 37279366